Weatherly Asset Management L. P. Buys 532 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Weatherly Asset Management L. P. grew its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 0.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 157,945 shares of the exchange traded fund’s stock after buying an additional 532 shares during the period. SPDR S&P Biotech ETF accounts for about 1.3% of Weatherly Asset Management L. P.’s investment portfolio, making the stock its 21st largest position. Weatherly Asset Management L. P. owned about 0.21% of SPDR S&P Biotech ETF worth $14,225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of XBI. Hartline Investment Corp raised its stake in SPDR S&P Biotech ETF by 2.0% during the third quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock valued at $544,000 after purchasing an additional 106 shares in the last quarter. Signature Estate & Investment Advisors LLC raised its stake in SPDR S&P Biotech ETF by 5.7% during the third quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock valued at $231,000 after purchasing an additional 125 shares in the last quarter. Denver Wealth Management Inc. raised its stake in SPDR S&P Biotech ETF by 0.9% during the third quarter. Denver Wealth Management Inc. now owns 14,779 shares of the exchange traded fund’s stock valued at $1,460,000 after purchasing an additional 127 shares in the last quarter. Trust Co. of Vermont raised its stake in SPDR S&P Biotech ETF by 4.7% during the third quarter. Trust Co. of Vermont now owns 3,058 shares of the exchange traded fund’s stock valued at $302,000 after purchasing an additional 138 shares in the last quarter. Finally, Graypoint LLC raised its stake in SPDR S&P Biotech ETF by 5.6% during the third quarter. Graypoint LLC now owns 2,738 shares of the exchange traded fund’s stock valued at $271,000 after purchasing an additional 146 shares in the last quarter.

SPDR S&P Biotech ETF Stock Down 1.0 %

SPDR S&P Biotech ETF stock opened at $90.34 on Tuesday. The company has a market cap of $6.89 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The firm’s fifty day moving average is $92.40 and its 200 day moving average is $96.38. SPDR S&P Biotech ETF has a 52-week low of $81.14 and a 52-week high of $105.47.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.